<DOC>
	<DOCNO>NCT00136461</DOCNO>
	<brief_summary>The purpose study assess effect combination all-trans retinoic acid combination one two schedule Bryostatin 1 patient myelodysplasia acute myelogenous leukemia .</brief_summary>
	<brief_title>A Study All-Trans Retinoic Acid ( ATRA ) Bryostatin Patients With Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>All patient receive all-trans retinoic acid dose 150 mg/m2/day patient randomize one two schedule Bryostatin 1 . Arm 1 : Bryostatin 1 administer dose 60 mcg/m2 30 minute intravenous ( IV ) infusion day 8 22 . Arm 2 : Bryostatin 1 administer dose 40 mcg/m2 72 hour IV infusion start day 8 22 . Patients assessed response day +50 bone marrow examination patient either clinical response stable disease receive therapy . Bryostatin 1 pharmacokinetic sample draw day 1 , 8 50 cycle .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Patients AML fail induction chemotherapy . Patients secondary AML Patients AML age 60 deemed candidate chemotherapy . Patients subtype MDS . Age 18 great . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Satisfactory liver kidney function . Greater 4 week prior chemotherapy radiation therapy . Central nervous system abnormality . Uncontrolled active infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>AML</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>bryostatin 1</keyword>
	<keyword>all-trans retinoic acid</keyword>
	<keyword>ATRA</keyword>
</DOC>